BillionToOne, Inc. Class A Common Stock (BLLN)vsDanaher Corporation (DHR)
BLLN
BillionToOne, Inc. Class A Common Stock
$114.00
-0.06%
HEALTHCARE · Cap: $4.77B
DHR
Danaher Corporation
$236.95
+1.23%
HEALTHCARE · Cap: $161.01B
Smart Verdict
WallStSmart Research — data-driven comparison
Danaher Corporation generates 6218% more annual revenue ($25.11B vs $397.41M). DHR leads profitability with a 16.0% profit margin vs 8.3%. DHR trades at a lower P/E of 40.8x. DHR earns a higher WallStSmart Score of 66/100 (B-).
BLLN
Hold38
out of 100
Grade: F
DHR
Strong Buy66
out of 100
Grade: B-
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 64.4% year-over-year
Conservative balance sheet, low leverage
Earnings expanding 59.7% YoY
Large-cap with strong market position
Generating 1.6B in free cash flow
Areas to Watch
Trading at 9.9x book value
0.0% earnings growth
ROE of 5.0% — below average capital efficiency
Premium valuation, high expectations priced in
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : BLLN
The strongest argument for BLLN centers on Revenue Growth, Debt/Equity. Revenue growth of 64.4% demonstrates continued momentum.
Bull Case : DHR
The strongest argument for DHR centers on EPS Growth, Market Cap, Free Cash Flow. Profitability is solid with margins at 16.0% and operating margin at 19.8%. PEG of 1.32 suggests the stock is reasonably priced for its growth.
Bear Case : BLLN
The primary concerns for BLLN are Price/Book, EPS Growth, Return on Equity. A P/E of 160.4x leaves little room for execution misses.
Bear Case : DHR
The primary concerns for DHR are P/E Ratio. A P/E of 40.8x leaves little room for execution misses.
Key Dynamics to Monitor
BLLN profiles as a hypergrowth stock while DHR is a mature play — different risk/reward profiles.
BLLN is growing revenue faster at 64.4% — sustainability is the question.
DHR generates stronger free cash flow (1.6B), providing more financial flexibility.
Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.
Bottom Line
DHR scores higher overall (66/100 vs 38/100), backed by strong 16.0% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BillionToOne, Inc. Class A Common Stock
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company is headquartered in Menlo Park, California.
Danaher Corporation
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.
Compare with Other DIAGNOSTICS & RESEARCH Stocks
Want to dig deeper into these stocks?